{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:49:37Z","timestamp":1790617777094,"version":"4.1.0"},"reference-count":16,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.2967\/jnumed.123.267234","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:35:20Z","timestamp":1713461720000},"page":"917-922","source":"Crossref","is-referenced-by-count":28,"title":["RECIP 1.0 Predicts Progression-Free Survival After [<sup>177<\/sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"65","author":[{"given":"Andrei","family":"Gafita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Djaileb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias R.","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"2024060510401905000_65.6.917.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024060510401905000_65.6.917.2","unstructured":"FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer. Updated May 27, 2021. Accessed April 3, 2024."},{"key":"2024060510401905000_65.6.917.3","unstructured":"FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer. Updated December 1, 2020. Accessed April 3, 2024."},{"key":"2024060510401905000_65.6.917.4","unstructured":"Drug Trials Snapshot: POSLUMA. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-posluma. Updated January 16, 2024. Accessed April 3, 2024."},{"key":"2024060510401905000_65.6.917.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2024060510401905000_65.6.917.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2024060510401905000_65.6.917.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2024060510401905000_65.6.917.8","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401905000_65.6.917.9","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response Evaluation Criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2024060510401905000_65.6.917.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265874"},{"key":"2024060510401905000_65.6.917.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265155"},{"key":"2024060510401905000_65.6.917.12","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1007\/s00259-023-06382-2","article-title":"Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images","volume":"50","author":"Kendrick","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401905000_65.6.917.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"2024060510401905000_65.6.917.14","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.1002\/cnr2.1334","article-title":"Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer","volume":"4","author":"Maeda","year":"2021","journal-title":"Cancer Rep."},{"key":"2024060510401905000_65.6.917.15","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2022.40.16_suppl.5000","article-title":"TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: overall survival after median follow-up of 3 years (ANZUP 1603) [abstract]","volume":"40","author":"Hofman","year":"2022","journal-title":"J Clin Oncol."},{"key":"2024060510401905000_65.6.917.16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bju.15491","article-title":"ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)","volume":"128","author":"Emmett","year":"2021","journal-title":"BJU Int."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.267234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:43:05Z","timestamp":1717609385000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.267234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.2967\/jnumed.123.267234"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.267234","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}